In re Effexor XR Antitrust Litigation

Brief of the Federal Trade Commission as amicus curiae before the United States District Court for the District of New Jersey, addressing the question of whether a branded company's commitment not to launch an authorized generic in competition with a generic company can be a reverse payment under the Supreme Court’s ruling in FTC v. Actavis, 133 S. Ct. 2223 (2013)